Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Series B pulls in $25mm for Resolvyx; adds $4mm

Executive Summary

Resolvyx Pharmaceuticals (developing therapies for inflammatory diseases and related complications) raised $25mm through its Series B financing round led by first-time backer QVT, which contributes a member to the company's board. Other new investors Radius Ventures and Biogen Idec New Ventures were joined by returning shareholders Atlas Venture, CHL Medical Partners, and Flagship Ventures.
Deal Industry
  • Biotechnology
  • Pharmaceuticals
Deal Status
  • Final
Deal Type
  • Financing
    • Venture Financing

Related Companies